A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination With Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas
Latest Information Update: 26 Sep 2022
At a glance
- Drugs CDX 301 (Primary) ; Poly ICLC (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 21 Sep 2022 Status changed from recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 1 Nov 2020 to 1 Nov 2022.
- 17 Nov 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2022.